Compare iShares China Large-Cap ETF (FXI) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares China Large-Cap ETF trades at $34.27 (market cap $3.86B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 10.5× iShares China Large-Cap ETF's market cap, and iShares China Large-Cap ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FXI | IDXX | |
|---|---|---|
Market Cap | $3.86B | $40.43B |
Volume | 16,323,837 | 692,164 |
52-Week High | $41.08 | $766.68 |
52-Week Low | $31.59 | $504.70 |
Typical Hold Time | 150 Days | 46 Days |
Sector | — | Health |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $34.19, up 2.3% today, but technical indicators show a bearish trend with 17 sell signals versus 1 buy. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent U.S.-China diplomatic engagement offers potential for reduced trade tensions, but momentum remains weak with the ETF trading near key support at $33.
FXI presents a value opportunity trading at half the S&P 500's P/E ratio with a 1.98% yield, but requires tolerance for significant geopolitical risk. The ETF's heavy financial sector exposure and China's export-driven economy face protectionism threats, making it suitable only for diversified portfolios with high risk tolerance.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
